睿昂基因
(688217)
| 流通市值：13.72亿 | | | 总市值：13.72亿 |
| 流通股本：5585.59万 | | | 总股本：5585.59万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 54,738,007.28 | 242,306,170.99 | 189,630,100.09 | 134,790,886.33 |
| 营业收入 | 54,738,007.28 | 242,306,170.99 | 189,630,100.09 | 134,790,886.33 |
| 二、营业总成本 | 55,633,595.22 | 250,955,636.13 | 192,926,333.51 | 129,763,652.75 |
| 营业成本 | 15,872,484.58 | 61,719,324.93 | 45,358,535.96 | 33,545,031.62 |
| 税金及附加 | 744,348.76 | 2,281,058.53 | 1,739,761.86 | 1,201,487.84 |
| 销售费用 | 13,062,526.52 | 72,899,960.24 | 59,338,974.8 | 38,555,399.38 |
| 管理费用 | 14,777,043.39 | 54,422,369.06 | 40,734,119.55 | 23,691,389.01 |
| 研发费用 | 10,988,068.94 | 62,470,671.03 | 46,854,439.7 | 34,201,238.57 |
| 财务费用 | 189,123.03 | -2,837,747.66 | -1,099,498.36 | -1,430,893.67 |
| 其中:利息费用 | - | 884,673.47 | - | 482,358.85 |
| 其中:利息收入 | - | 3,171,198.17 | - | 1,726,565.36 |
| 加:公允价值变动收益 | 54,991.97 | 872,958.26 | -233,417.5 | -567,339.97 |
| 加:投资收益 | 495,024 | 1,618,455.25 | 1,781,659.3 | 1,508,089.08 |
| 资产处置收益 | 62,237.97 | 119,222.25 | 278,041.12 | 101,435.93 |
| 资产减值损失(新) | -120,852.61 | -17,771,809.12 | -654,429.15 | -689,119.2 |
| 信用减值损失(新) | 115,963.27 | -6,841,777.83 | -5,517,111.95 | -6,185,884.74 |
| 其他收益 | 2,085,239.6 | 2,230,560.15 | 4,059,030.2 | 3,814,669.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 1,797,016.26 | -28,421,856.18 | -3,582,461.4 | 3,009,084.08 |
| 加:营业外收入 | 76.18 | 241,571.49 | 286,199.36 | 276,197.9 |
| 减:营业外支出 | 15,850.01 | 294,250.75 | 69,377.15 | 64,717.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 1,781,242.43 | -28,474,535.44 | -3,365,639.19 | 3,220,564.03 |
| 减:所得税费用 | -60,186.88 | -2,567,809.34 | -4,913,175.71 | -2,586,485.7 |
| 六、净利润 | 1,841,429.31 | -25,906,726.1 | 1,547,536.52 | 5,807,049.73 |
| 持续经营净利润 | 1,841,429.31 | -25,906,726.1 | 1,547,536.52 | 5,807,049.73 |
| 归属于母公司股东的净利润 | 3,355,013.27 | -15,764,502.19 | 5,727,339.64 | 9,221,789.85 |
| 少数股东损益 | -1,513,583.96 | -10,142,223.91 | -4,179,803.12 | -3,414,740.12 |
| (一)基本每股收益 | 0.06 | -0.28 | 0.1 | 0.17 |
| (二)稀释每股收益 | 0.06 | -0.28 | 0.1 | 0.17 |
| 九、综合收益总额 | 1,841,429.31 | -25,906,726.1 | 1,547,536.52 | 5,807,049.73 |
| 归属于母公司股东的综合收益总额 | 3,355,013.27 | -15,764,502.19 | 5,727,339.64 | 9,221,789.85 |
| 归属于少数股东的综合收益总额 | -1,513,583.96 | -10,142,223.91 | -4,179,803.12 | -3,414,740.12 |
| 公告日期 | 2025-04-25 | 2025-04-18 | 2024-10-30 | 2024-08-30 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |